List of Excipients in Branded Drug CLIMARA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	CLIMARA PRO	estradiol and levonorgestrel	54868-5570	POVIDONE

Last updated: September 24, 2026

Climara is an estradiol transdermal system whose commercial value depends more on adhesion, dose uniformity, skin permeation, wear time, and patient convenience than on the active ingredient. The core opportunity is a differentiated matrix patch that improves adhesion during bathing and exercise, reduces skin irritation, limits residue, and maintains stable estradiol delivery across five approved strengths. Generic entry has materially reduced the value of the legacy product, while excipient and device engineering remain viable routes for premium positioning, authorized-generic supply, and lifecycle extensions.

Climara Excipient Strategy and Commercial Opportunities

What is Climara and how does its transdermal system work?

Climara is a once-weekly estradiol transdermal system marketed for systemic estrogen replacement therapy. The product delivers estradiol through the skin and is available in five strengths:

Climara strength	Nominal delivery rate	Weekly estradiol delivery
Climara 0.025	0.025 mg/day	0.175 mg/week
Climara 0.0375	0.0375 mg/day	0.2625 mg/week
Climara 0.05	0.05 mg/day	0.35 mg/week
Climara 0.075	0.075 mg/day	0.525 mg/week
Climara 0.1	0.1 mg/day	0.7 mg/week

The system is applied once weekly to the lower abdomen or buttocks. The product is a drug-in-adhesive matrix patch. Estradiol is incorporated into the adhesive layer rather than held in a separate liquid or gel reservoir. The backing layer protects the drug-containing matrix, while the release liner is removed before application. The FDA-approved labeling identifies estradiol, an acrylic adhesive matrix, a polyester backing, and a fluoropolymer-coated polyester release liner as core system components.[1]

The commercial performance of a Climara-type product is determined by:

• Estradiol solubility and dispersion in the adhesive.
• Drug release from the matrix.
• Skin permeation and depot formation in the stratum corneum.
• Adhesion over seven days.
• Resistance to water, sweat, friction, and clothing.
• Skin tolerability after patch removal.
• Consistent delivery across the labeled dose range.

What excipients are used in Climara patches?

Climara’s excipient strategy is built around an acrylic pressure-sensitive adhesive that performs several functions at once. It holds the patch on the skin, solubilizes or disperses estradiol, controls drug release, and supports transdermal flux.

Climara component architecture

Component	Primary function	Commercial importance
Estradiol	Active pharmaceutical ingredient	Determines dose and therapeutic delivery
Acrylic adhesive matrix	Adhesion, drug incorporation, release control	Main formulation and performance variable
Polyester backing	Mechanical protection and occlusion control	Influences durability and handling
Fluoropolymer-coated polyester liner	Protects adhesive before use	Affects manufacturing, peel behavior, and packaging
Packaging pouch	Protects against moisture, oxygen, and contamination	Important for shelf life and stability

The label does not present Climara as a conventional tablet formulation with multiple functional excipients. Most product differentiation sits in the adhesive matrix and the patch construction. That creates a narrower excipient platform than an oral dosage form but increases the importance of polymer selection and coating-process control.

Which excipient strategies can improve a Climara-type product?

Acrylic adhesive optimization

Acrylic pressure-sensitive adhesives remain the most direct platform for a generic or improved Climara product. Formulators can adjust the balance among:

• Estradiol solubility.
• Adhesive tack.
• Cohesive strength.
• Peel adhesion.
• Drug diffusion.
• Skin irritation.
• Residual adhesive after removal.

A higher-solubility adhesive can improve dose uniformity but may change estradiol release and skin flux. A more aggressive adhesive can reduce patch lift but increase erythema, itching, and removal discomfort. The commercial objective is not maximum adhesion. It is sufficient seven-day adhesion with low irritation and clean removal.

Silicone adhesive systems

Silicone adhesives can offer improved skin tolerability and clean removal compared with some acrylic systems. Their limitations include lower compatibility with certain active concentrations, different drug solubility behavior, and potentially higher raw-material cost.

A silicone-based Climara alternative could target patients who discontinue acrylic patches because of dermatitis or adhesive residue. The product would require careful control of estradiol crystallization, since limited drug solubility can produce visible particles, dose nonuniformity, or changing release rates during storage.

Polyisobutylene systems

Polyisobutylene adhesives are used in some transdermal systems because of their cohesive strength and chemical stability. They can support robust adhesion but may require formulation changes to achieve the same estradiol release profile as an acrylic matrix. Their commercial value would depend on improved adhesion or tolerability that can be demonstrated without sacrificing weekly delivery.

Permeation enhancers

Permeation enhancers can increase estradiol flux and reduce patch area. Candidate approaches include fatty acids, fatty alcohols, glycols, terpenes, and other skin-permeation modifiers. These materials create a direct tradeoff between delivery efficiency and irritation risk.

A permeation enhancer is most commercially useful when it enables one of four outcomes:

1. A smaller patch.
2. A lower total estradiol load.
3. More consistent delivery across patients.
4. A longer wear period without increasing patch size.

The enhancer must remain compatible with the adhesive, liner, backing, pouch, and accelerated stability conditions.

Alternative backing films

Backing materials can improve water resistance, flexibility, and skin conformity. A thinner or more elastic polyester, polyurethane, or multilayer film may reduce edge lift during movement. A transparent or skin-colored backing can also improve cosmetic acceptance.

Backing changes can create regulatory complexity because they may alter occlusion, drug release, moisture transmission, and skin permeation. A new backing is more defensible commercially when it produces measurable improvements in wear time or patient satisfaction.

Low-irritation adhesive systems

A major opportunity is a low-sensitization patch that reduces erythema and itching. Potential design approaches include:

• Lower residual monomer levels.
• Reduced adhesive coat weight.
• Silicone or hybrid adhesive systems.
• Fewer formulation additives.
• More neutral adhesive chemistry.
• Lower peel force at removal.
• Improved release-liner transfer control.

For estrogen replacement therapy, low irritation may have greater commercial value than a small reduction in patch size because patients often use the product chronically.

What formulation patents protect Climara-type products?

The strongest formulation protection for a transdermal estradiol product generally comes from claims directed to:

• Estradiol concentration in an adhesive matrix.
• Specific acrylic or silicone polymer compositions.
• Drug-to-polymer ratios.
• Patch area and delivery rate.
• Seven-day administration.
• Specific backing and release-liner combinations.
• Reduced skin irritation.
• Adhesive performance after exposure to water.
• Manufacturing methods that produce uniform drug distribution.
• Combination therapy with a progestogen or other hormone.

Legacy Climara protection was associated with transdermal estradiol technology developed by Schering and later commercialized by Bayer. The principal U.S. product patent and regulatory exclusivity period have expired, and Climara now competes in a generic market. The current commercial barrier is therefore formulation know-how and regulatory equivalence rather than a long-lived blocking patent estate.

A new product may still obtain patents if it has a technically specific improvement. Broad claims covering "estradiol in a transdermal adhesive patch" are vulnerable to prior-art and obviousness challenges. Narrower claims covering a defined polymer blend, drug-loading range, adhesive performance, or manufacturing parameter are more likely to support enforceable protection.

When does Climara lose exclusivity and what is the Orange Book status?

Climara’s original small-molecule exclusivity has expired. The product is regulated under an FDA new drug application and is exposed to abbreviated new drug application competition. FDA’s Orange Book identifies approved drug products, patent information, and regulatory exclusivity relevant to generic competition.[2]

For business planning, Climara should be treated as a mature product with:

• No meaningful remaining new-chemical-entity exclusivity.
• Established generic substitution risk.
• Limited value from legacy patent rights.
• Continuing value in brand recognition, supply reliability, and patient familiarity.
• Potential lifecycle value from improved delivery systems rather than the original product alone.

An ANDA applicant must generally demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. For a transdermal system, the development burden includes more than matching the estradiol strength. The applicant must control patch construction, adhesive performance, residual drug, release behavior, and systemic exposure.[3]

What generic entry risks exist for Climara?

Generic competition affects Climara through price erosion, formulary substitution, and loss of pharmacy-level preference. Transdermal estradiol is particularly exposed because multiple products can compete on the same active ingredient and delivery route.

Generic entry pressure points

Risk area	Effect on Climara
Multiple strengths	Increases substitution opportunities across dose tiers
Weekly dosing	Creates a clear therapeutic alternative to branded supply
Mature active ingredient	Limits active-ingredient differentiation
Patch formulation	Allows differentiation through adhesion and tolerability
Pharmacy substitution	Can shift prescriptions without physician intervention
Payer contracting	Encourages lowest-net-cost products
Patient attachment to brand	Provides some resistance to automatic substitution

The most important generic quality risks are patch detachment, skin reactions, visible residue, dose variability, and inconsistent delivery late in the wear period. A branded or premium generic product that documents better adhesion and tolerability can defend a price premium if physicians, payers, or patients perceive a meaningful clinical benefit.

Which companies compete with Climara?

The competitive field includes branded and generic transdermal estradiol products, as well as non-patch estrogen delivery systems.

Product category	Examples	Competitive basis
Weekly estradiol patches	Climara and generic equivalents	Convenience and weekly dosing
Twice-weekly estradiol patches	Vivelle-Dot and generic equivalents	Smaller patch size and frequent replacement
Estradiol gels	EstroGel, Divigel, generic products	No adhesive patch and flexible dosing
Estradiol sprays	Evamist	Spray-based administration
Vaginal estrogen	Creams, tablets, rings	Primarily local therapy
Oral estrogen	Estradiol tablets and combinations	Low cost and prescribing familiarity

Climara’s weekly schedule is a meaningful convenience advantage over twice-weekly patches. Its larger patch footprint can be a disadvantage when patients prioritize cosmetic appearance or experience edge lift.

A new weekly patch can compete by improving one of three measurable product attributes: adhesion, skin tolerability, or patch size. A generic that simply matches Climara may win on price, but a differentiated product can compete on total treatment experience.

How strong is the patent estate for a new Climara excipient platform?

A new excipient platform can have moderate patent value if it is tied to reproducible performance data. The strongest patent strategy would use multiple claim layers:

Composition claims

Claims may cover:

• Estradiol concentration.
• Acrylic, silicone, or hybrid adhesive identity.
• Crosslinker or tackifier ranges.
• Permeation-enhancer concentration.
• Polymer molecular-weight ranges.
• Drug-to-adhesive ratios.

System claims

Claims may cover:

• Patch area.
• Backing thickness.
• Adhesive coat weight.
• Weekly wear period.
• Delivered estradiol amount.
• Adhesion after water exposure.
• Residual drug content.

Method claims

Claims may cover:

• Manufacturing and coating conditions.
• Drying temperature and residence time.
• Mixing sequence.
• Crystallization control.
• Packaging under controlled humidity.
• Application to a defined body site.
• Treatment of menopausal symptoms with the system.

Data needed to support commercial patent value

A credible patent position requires comparative evidence against Climara or a representative generic. Useful data include:

• Seven-day adhesion testing.
• Peel-force and tack measurements.
• Water-resistance testing.
• In vitro release.
• In vitro skin permeation.
• Estradiol plasma exposure.
• Residual drug uniformity.
• Skin irritation and sensitization results.
• Stability under high temperature and humidity.
• Patient preference and patch-lift rates.

What FDA regulatory pathway applies to a new Climara-type product?

A product intended to substitute for Climara can pursue an ANDA if it meets the applicable requirements for pharmaceutical equivalence and bioequivalence. A product with a materially different formulation, delivery profile, indication, or clinical claim may require a 505(b)(2) application.

ANDA opportunity

An ANDA is most attractive when the proposed system matches the reference product in:

• Dosage form.
• Route of administration.
• Strength.
• Delivery duration.
• Active ingredient.
• Relevant performance attributes.

The commercial advantage is lower clinical-development cost relative to a new drug application. The tradeoff is limited freedom to make clinically meaningful formulation changes.

505(b)(2) opportunity

A 505(b)(2) strategy may support:

• A new adhesive platform.
• A smaller or thinner patch.
• A longer wear period.
• A new dose strength.
• Improved tolerability.
• A different delivery schedule.
• A new combination with a progestogen.

The product must still establish safety, efficacy, quality, and performance. The regulatory pathway can support stronger differentiation but usually requires more development and a clearer clinical rationale.

What commercial opportunities exist for Climara excipients?

Premium generic

A premium generic can target patients who report patch lift, irritation, or residue with existing products. The value proposition should be measurable, such as a lower detachment rate or improved skin tolerability.

Authorized generic

An authorized generic can use the established Climara formulation and supply chain while competing on price. This strategy has lower technical risk but limited differentiation and generally lower margins.

Excipient licensing

An excipient supplier can license:

• A low-irritation acrylic adhesive.
• A silicone-estradiol matrix.
• A high-flux permeation-enhancer system.
• A water-resistant backing film.
• A coatable polymer with improved drug uniformity.
• A packaging system that improves shelf life.

The most valuable licensing package includes formulation know-how, analytical methods, coating parameters, and regulatory support. A polymer alone is easier to substitute and usually commands less value.

Contract development and manufacturing

Transdermal patch manufacturers can offer integrated development covering:

• Adhesive screening.
• Coating and drying.
• Slitting and die cutting.
• Pouching.
• Stability studies.
• Extractables and leachables.
• Scale-up.
• Commercial release testing.

Manufacturing capability is a meaningful barrier because patch production requires control of coat weight, web handling, adhesive transfer, liner release, and unit-dose packaging.

Patient-centric lifecycle extension

A new Climara-type product could target:

• Smaller patch size.
• Transparent or skin-colored construction.
• Seven-day water-resistant wear.
• Lower skin irritation.
• Easier removal.
• More stable estradiol delivery.
• Improved performance in hot or humid climates.

Each claim should be supported by comparative testing. Convenience alone is unlikely to justify durable pricing without a clear adherence or patient-preference benefit.

What manufacturing and intellectual-property barriers affect Climara alternatives?

The principal manufacturing barriers are process control and scale-up, not raw-material availability. Estradiol is an established active ingredient, and acrylic and silicone adhesive technologies are commercially available. The difficult steps are:

• Achieving uniform low-dose estradiol distribution.
• Preventing crystallization during storage.
• Maintaining consistent adhesive coat weight.
• Controlling residual solvent.
• Preventing liner or backing defects.
• Preserving adhesion after packaging and aging.
• Demonstrating reproducible transdermal delivery.

The main intellectual-property risks involve adhesive composition, patch geometry, manufacturing parameters, and claims directed to improved delivery. Freedom-to-operate analysis should cover U.S., European, Japanese, and other major hormone-replacement markets because patent scope and regulatory requirements vary by jurisdiction.

What revenue exposure does Climara face from generic competition?

Climara revenue is exposed to generic substitution because the active ingredient is mature, the product is routinely prescribed, and multiple transdermal alternatives exist. Revenue defense depends on:

• Brand loyalty.
• Payer coverage.
• Supply reliability.
• Dose availability.
• Patient tolerability.
• Physician confidence in patch performance.
• Differentiated delivery technology.

The strongest commercial strategy is usually a portfolio rather than a single patch. A company could combine a low-cost generic, a premium low-irritation patch, and a smaller patch for cosmetic-sensitive users. That approach captures price-sensitive and performance-sensitive segments without relying on one product profile.

How does Climara compare with other estradiol delivery systems?

Attribute	Climara-type weekly patch	Twice-weekly patch	Estradiol gel	Oral estradiol
Dosing frequency	Weekly	Twice weekly	Daily	Daily
First-pass hepatic exposure	Avoided	Avoided	Avoided	Present
Adhesive risk	Present	Present	None	None
Dose flexibility	Moderate	Moderate	Higher	High
Visible residue	Possible	Possible	Possible transfer
Manufacturing complexity	High	High	Moderate	Lower
Generic substitution risk	High	High	Increasing	Very high
Main differentiation route	Adhesion and tolerability	Size and comfort	Application and transfer control	Cost and dose flexibility

Climara’s central competitive advantage is weekly dosing. Its central weakness is dependence on long-duration adhesive performance.

Key Takeaways

• Climara is a weekly estradiol matrix patch with five marketed strengths.
• The acrylic adhesive is the principal excipient and the main source of formulation differentiation.
• Legacy exclusivity has expired, and generic substitution is the dominant commercial threat.
• The strongest product opportunities involve low-irritation adhesion, smaller patch size, improved water resistance, and consistent seven-day delivery.
• A new excipient platform is more defensible when supported by composition, system, manufacturing, and performance claims.
• ANDA development is appropriate for close substitutes; 505(b)(2) development is more suitable for meaningful formulation or delivery improvements.
• Excipient licensing, premium generics, authorized generics, and contract manufacturing are the main commercial routes.
• Patent value will depend on narrow technical claims and comparative adhesion, permeation, stability, and tolerability data.

FAQs

Can a new Climara patch use a different adhesive?

Yes. A different acrylic, silicone, polyisobutylene, or hybrid adhesive may be used if the product meets applicable quality, bioequivalence, safety, and performance requirements. A materially different adhesive may support a 505(b)(2) strategy rather than a straightforward ANDA.

Is Climara’s acrylic adhesive the main source of product performance?

Yes. The adhesive controls attachment, estradiol incorporation, drug release, skin permeation, residue, and much of the product’s skin-tolerability profile.

What is the best excipient opportunity for a generic Climara product?

A low-irritation, water-resistant adhesive with reliable seven-day adhesion offers the clearest commercial opportunity. A smaller patch can add value if it maintains equivalent delivery and improves patient acceptance.

Can a Climara alternative obtain new patents after the original product patents expire?

Yes. New patents may cover a distinct adhesive composition, polymer blend, permeation-enhancer system, patch architecture, manufacturing process, or demonstrated performance improvement. Broad claims covering estradiol patches generally face stronger prior-art risk.

Are biosimilar requirements relevant to Climara?

No. Climara contains estradiol, a small-molecule active ingredient, and is not a biologic. The relevant competition is generic or follow-on drug competition under FDA small-molecule pathways, not biosimilar substitution.

References

1. Bayer HealthCare Pharmaceuticals Inc. (2023). Climara (estradiol transdermal system) prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2022). Bioequivalence studies with pharmacokinetic endpoints for transdermal delivery systems. FDA guidance and product-specific regulatory materials.

4. U.S. Food and Drug Administration. (2024). Approved drug products database and Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs/abbreviated-new-drug-application-anda-process